Disease · MONDO_0015925
interstitial lung disease
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. interstitial lung disease. Diseases, record MONDO_0015925. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015925
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Abnormal lung parenchyma morphology, Abnormal pulmonary interstitial morphology, Abnormality in area between air sacs in lung, ILD, Interstitial pulmonary disease, lung disease, interstitial, lung diseases, interstitial
- Open Targets
- Highest stage of its drugs
- Approval, for 1 of its 57 drugs, from ClinicalTrials.gov and EMA Human Drugs
- Open Targets
Drugs57
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NINTEDANIB | CHEMBL502835 | Small molecule | Approval | ClinicalTrials.gov and EMA Human Drugs | 14 | 11 | 11 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| BELIMUMAB | CHEMBL1789843 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| PIRFENIDONE | CHEMBL1256391 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| NERANDOMILAST | CHEMBL5314532 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TOCILIZUMAB | CHEMBL1237022 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| FENTANYL | CHEMBL596 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FENTANYL CITRATE | CHEMBL688 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 57
See all 57 drugsTargets127
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 6 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 3 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/5159 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/2324 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 2 | Soluble guanylate cyclase activator; Soluble guanylate cyclase positive allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 2 | Soluble guanylate cyclase activator; Soluble guanylate cyclase positive allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 2 | Soluble guanylate cyclase activator; Soluble guanylate cyclase positive allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2983 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Phase 2 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3791 | Drugs and targets |
1 to 10 of 127
See all 127 targetsTrials77
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03313180 | A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis | Phase 3 | 444 | 2024-02-20 | Lung Diseases, Interstitial | NINTEDANIB | Its record names the disease | ClinicalTrials.gov |
| NCT02630316 | Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE | Phase 2/3 | 326 | 2021-07-13 | Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema | TREPROSTINIL | Its record names the disease | ClinicalTrials.gov |
| NCT03099187 | A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease | Phase 2 | 253 | 2020-01-03 | Lung Diseases, Interstitial | PIRFENIDONE | Its record names the disease | ClinicalTrials.gov |
| NCT02633293 | An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE | Phase 2/3 | 243 | 2022-12-02 | Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema | TREPROSTINIL | Its record names the disease | ClinicalTrials.gov |
| NCT00004563 | Scleroderma Lung Disease | Phase 3 | 158 | 2015-03-06 | Lung Diseases, Pulmonary Fibrosis, Systemic Scleroderma, Scleroderma, Systemic | CYCLOPHOSPHAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00883129 | Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) | Phase 2 | 142 | 2017-02-10 | Scleroderma, Interstitial Lung Disease | CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov |
| NCT02808871 | Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1) | Phase 2 | 123 | 2022-08-16 | Rheumatoid Arthritis Interstitial Lung Disease | PIRFENIDONE | Its record names the disease | ClinicalTrials.gov |
| NCT04702893 | INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation | 108 | 2025-04-25 | Lung Diseases, Interstitial | NINTEDANIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03384940 | DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | Phase 2 | 86 | 2021-08-24 | Colorectal Neoplasm | TRASTUZUMAB DERUXTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT05285982 | A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON) | Phase 3 | 54 | 2026-03-04 | Lung Diseases, Interstitial | NINTEDANIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 77
See all 77 trialsComparisons in its trials28
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Inhaled Treprostinil vs Placebo: Incidence of Clinical Worsening | 37 of 163 | 54 of 163 | 326 | NCT02630316 | Trial comparisons |
| Active Inhaled Treprostinil vs Placebo: deaths from any cause | 10 of 163 | 12 of 163 | 326 | NCT02630316 | Trial comparisons |
| Active Inhaled Treprostinil vs Placebo: serious adverse events | 38 of 163 | 42 of 163 | 326 | NCT02630316 | Trial comparisons |
| Pirfenidone vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 120 of 127 | 101 of 124 | 251 | NCT03099187 | Trial comparisons |
| Cylophosphamide vs Placebo: serious adverse events | 5 of 79 | 5 of 79 | 158 | NCT00004563 | Trial comparisons |
| Mycophenolate Arm vs Cyclophosphamide Arm: serious adverse events | 27 of 69 | 22 of 73 | 142 | NCT00883129 | Trial comparisons |
| Pirfenidone vs Placebo: Hospitalization for Respiratory Cause | 2 of 63 | 5 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Number of Participants Who Developed Any Element of the Composite Endpoint | 7 of 63 | 9 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: All-cause Mortality | 2 of 63 | 3 of 60 | 123 | NCT02808871 | Trial comparisons |
| Pirfenidone vs Placebo: Number of Participants With Progressive Disease | 16 of 63 | 19 of 60 | 123 | NCT02808871 | Trial comparisons |
1 to 10 of 28
See all 28 comparisons in its trialsPapers from its trials70
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015925
GET https://conductscience.org/api/diseases/v1/MONDO_0015925/drugs?page=2